ACC Action Center
Welcome to the ACC Action Center, bringing you the latest updates from the American College of Cardiology’s Annual Scientific Session & Expo, hosted in partnership with the World Congress of Cardiology. This collection will highlight emerging clinical data and explore the latest practice-changing advances in the field of cardiology.
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC Action CenterPhase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Low-dose apixaban noninferior to full dose in cancer-associated VTE
ACC Action CenterLow-dose apixaban noninferior to full dose in cancer-associated VTE
AI model may accelerate risk stratification of coronary revascularization in ED
ACC Action CenterAI model may accelerate risk stratification of coronary revascularization in ED
Dapagliflozin reduces worsening HF in elderly TAVI patients
ACC Action CenterDapagliflozin reduces worsening HF in elderly TAVI patients
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
ACC Action CenterLorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
- 04/18/2025
- 04/17/2025
- 04/16/2025
- 04/16/2025
- 04/15/2025
- 04/15/2025